Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 13/20 | 0.55 |
| ▸ | RXRA | P19793 | 3/20 | 0.52 |
| ▸ | RXRB | P28702 | 2/20 | 0.52 |
| ▸ | RXRG | P48443 | 2/20 | 0.52 |
| ▸ | FFAR4 | Q5NUL3 | 5/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.46 |
| ▸ | RELA | Q04206 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1845436 | 0.85 | FFAR1 (0.65) | FFAR1RXRARXRBRXRGFFAR4 | |
| SCHEMBL21098761 | 0.82 | FFAR4 (0.51) | FFAR1FFAR4POLBNFKB1NFKB2 | |
| SCHEMBL1566761 | 0.82 | FFAR1 (0.73) | FFAR1RXRARXRBRXRGFFAR4 | |
| SCHEMBL7236542 | 0.80 | SLC13A5 (0.65) | FFAR1FFAR4 | |
| SCHEMBL26784179 | 0.79 | ABL1 (0.49) | RXRARXRBRXRG | |
| SCHEMBL4145328 | 0.78 | RXRA (0.78) | RXRARXRBRXRGLMNA | |
| SCHEMBL1841290 | 0.77 | FFAR1 (0.71) | FFAR1RXRARXRBRXRGFFAR4 | |
| SCHEMBL30792366 | 0.77 | FFAR1 (0.81) | FFAR1FFAR4LMNAL3MBTL1POLB | |
| SCHEMBL274471 | 0.77 | FFAR1 (0.81) | FFAR1FFAR4LMNAL3MBTL1POLB | |
| SCHEMBL1841217 | 0.77 | HRH3 (0.49) | FFAR1RXRARXRBRXRG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6645939-B1 | Very late antigen-4 (VLA) integrin antagonists; antiallergens, antiasthmatics, and antiinflammatory agents; multiple sclerosis, autoimmune disease treatment | MERCK & CO., INC. | 2003-11-11 | — | — | US | disclosed |